129 related articles for article (PubMed ID: 2084074)
21. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Gradishar WJ; Stephenson P; Glover DJ; Neuberg DS; Moore MR; Windschitl HE; Piel I; Abeloff MD
Cancer; 2001 Nov; 92(10):2517-22. PubMed ID: 11745184
[TBL] [Abstract][Full Text] [Related]
22. Mitomycin-C, vinblastine, and lonidamine as salvage treatment of advanced breast cancer. A pilot study.
Zaniboni A; Montini E; Simoncini E; Marpicati P; Arcangeli G; Meriggi F; Marini G
Am J Clin Oncol; 1990 Dec; 13(6):520-3. PubMed ID: 2122716
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of lonidamine in patients with metastatic renal cell carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
Weinerman BH; Eisenhauer EA; Besner JG; Coppin CM; Stewart D; Band PR
Cancer Treat Rep; 1986 Jun; 70(6):751-4. PubMed ID: 3524824
[TBL] [Abstract][Full Text] [Related]
24. Palbociclib: first global approval.
Dhillon S
Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
[TBL] [Abstract][Full Text] [Related]
25. The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
Newell DR; Mansi J; Hardy J; Button D; Jenns K; Smith IE; Picollo R; Catanese B
Semin Oncol; 1991 Apr; 18(2 Suppl 4):11-7. PubMed ID: 2031191
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of lonidamine with whole body hyperthermia in advanced cancer.
Robins HI; Longo WL; Lagoni RK; Neville AJ; Hugander A; Schmitt CL; Riggs C
Cancer Res; 1988 Nov; 48(22):6587-92. PubMed ID: 3180069
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of lonidamine in inoperable non-small-cell lung cancer.
Kokron O; Maca S; Scheiner W; De Gregorio M; Ciottoli GB
Oncology; 1984; 41 Suppl 1():86-9. PubMed ID: 6717902
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of lonidamine in metastatic prostatic carcinoma.
Stewart DJ; Aitken SE; Irvine AH; Moors DE; Futter NG
Invest New Drugs; 1991 Nov; 9(4):343-4. PubMed ID: 1804810
[No Abstract] [Full Text] [Related]
29. Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.
Carlson RW; Doroshow JH; Odujinrin OO; Flam MS; Malec M; Lamborn KR
Invest New Drugs; 1990 Nov; 8(4):387-9. PubMed ID: 2150672
[No Abstract] [Full Text] [Related]
30. Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
Lopez M; Vici P; Di Lauro L; Paoletti G; Gionfra T; Conti F; Carpano S; Pignatti F; Giannarelli D
Eur J Cancer; 1995 Sep; 31A(10):1611-4. PubMed ID: 7488410
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
[TBL] [Abstract][Full Text] [Related]
33. Weekly epirubicin plus lonidamine in advanced breast carcinoma.
Nisticò C; Garufi C; Milella M; D'Ottavio AM; Vaccaro A; Fabi A; Terzoli E
Breast Cancer Res Treat; 1999 Aug; 56(3):233-7. PubMed ID: 10573114
[TBL] [Abstract][Full Text] [Related]
34. Phase II study with lonidamine in the treatment of hormone-refractory prostatic cancer patients.
Boccardo F; Guarneri D; Pace M; Decensi A; Oneto F; Martorana G
Tumori; 1992 Apr; 78(2):137-9. PubMed ID: 1523706
[TBL] [Abstract][Full Text] [Related]
35. Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study.
Rowinsky EK; Grochow LB; Hantel A; Ettinger DS; Vito BL; Donehower RC
Invest New Drugs; 1989 Nov; 7(4):317-25. PubMed ID: 2599802
[TBL] [Abstract][Full Text] [Related]
36. Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer.
Gadducci A; Brunetti I; Muttini MP; Fanucchi A; Dargenio F; Giannessi PG; Conte PF
Eur J Cancer; 1994; 30A(10):1432-5. PubMed ID: 7833097
[TBL] [Abstract][Full Text] [Related]
37. Clinical trials. Experimental cancer therapies move to the front line.
Couzin-Frankel J
Science; 2012 Jan; 335(6066):282-3. PubMed ID: 22267789
[No Abstract] [Full Text] [Related]
38. Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.
Iaffaioli RV; Tortoriello A; Facchini G; Santangelo M; Bucci L; Fei L; Di Martino N; Mantovani G; Caponigro F
Breast Cancer Res Treat; 1995 Sep; 35(3):243-8. PubMed ID: 7579494
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
Sledge GW; Robert N; Sparano JA; Cobeligh M; Goldstein LJ; Neuberg D; Rowinsky E; Baughman C; McCaskill-Stevens W
Semin Oncol; 1994 Oct; 21(5 Suppl 8):15-8. PubMed ID: 7939756
[TBL] [Abstract][Full Text] [Related]
40. Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study.
Gardin G; Barone C; Nascimben O; Ianniello G; Sturba F; Contu A; Pronzato P; Rosso R
Eur J Cancer; 1996 Jan; 32A(1):176-7. PubMed ID: 8695230
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
